P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Extracellular adenosine triphosphate (ATP) functions as a novel danger signal that boosts antitumor immunity and can also directly kill tumor cells. We have previously reported that chronic exposure of tumor cells to ATP provokes P2X7-mediated tumor cell death, by as yet incompletely defined molecular mechanisms. METHODOLOGY/PRINCIPAL FINDINGS: Here, we show that acute exposure of tumor cells to ATP results in rapid cytotoxic effects impacting several aspects of cell growth/survival, leading to inhibition of tumor growth in vitro and in vivo. Using agonist and antagonist studies together with generation of P2X7 deficient tumor cell lines by lentiviral shRNA delivery system, we confirm P2X7 to be the central control node transmitting extracellular ATP signals. We identify that downstream intracellular signaling regulatory networks implicate two signaling pathways: the known P2X7-PI3K/AKT axis and remarkably a novel P2X7-AMPK-PRAS40-mTOR axis. When exposed to high levels of extracellular ATP, these two signaling axes perturb the balance between growth and autophagy, thereby promoting tumor cell death. CONCLUSIONS: Our study defines novel molecular mechanisms underpinning the antitumor actions of P2X7 and provides a further rationale for purine-based drugs in targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 2×
“mTOR is a well-known key player in many critical cellular processes such as proliferation, survival, autophagy, and metabolism [22,43].”
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 3×
“P2X7 develop metastatic disease more rapidly [9].”
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“One of the major issues in cancer therapy is that disruption of one signaling component often induces compensatory pathways because of negative feedback regulations (e.g. rapalogs [23,24]) or loss of suppressors (e.g. PTEN [54]).”
Mathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798 · cited 1×
“inhibiting xenograft tumor growth, reducing cancer metastases, and inducing regression of existing cancers) [40,41].”
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · cited 2×
“However, rapalog exposure unfortunately disrupts crucial negative feedback modulations causing subsequent activation of phosphatidylinositol-3-OH kinase (PI3K)/protein kinase B (AKT) and/or PI3K-mitogen-activated protein kinase (MAPK) pathways and ultimately leading to chemoresistance [23,24].”
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 2×
“Moreover, PI3K/AKT and AMPK pathways are the two well-established positive and negative upstream arms of mTOR, respectively [44,45].”
ATP drives lamina propria TH17 cell differentiation
Atarashi, K., Nishimura, J., Shima, T., Umesaki, Y., Yamamoto, M., Onoue, M., Yagita, H., Ishii, N., Evans, R., Honda, K., et al. (2008) · Nature · doi:10.1038/nature07240 · Cited by 1,089 · cited 1×
“by: 1) enhancing dendritic cell-primed tumor specific CD8 T cell cytotoxicity [9,10]; 2) acting as a ‘‘find-me’’ signal to phagocytes [11]; 3) induction of IL-1b release by monocytes [12,13]; 4) skewing of T helper (Th) cells towards type 1 (Th1) and type 17 (Th17) cells which are thought to promote antitumor immunity…”
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
Self-citationGuidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Self-citationExtracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis
Cadwell, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.100 · Cited by 475
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437
“, 2006), melanoma (White et al., 2009; Feng et al., 2011; Bian et al., 2013), squamous cell carcinomas (Deli and Csernoch, 2008), and glioma (Tamajusuku et al.”
BackgroundInfluentialThe role of microglial P2X7: modulation of cell death and cytokine release
He, Y., Taylor, N., Fourgeaud, L., & Bhattacharya, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0904-8 · Cited by 194
“8), which may be due to the context-dependent manner of these pathways such as in different cell types [38].”
Zha, Q.-B., Wei, H.-X., Li, C.-G., Liang, Y.-D., Xu, L.-H., Bai, W.-J., Pan, H., He, X.-H., & Ouyang, D.-Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00597 · Cited by 95
PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer
Kari, S., Vasko, V. V., Priya, S., & Kirschner, L. S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00769 · Cited by 34
Metadata
- Authors
- Bian, S., Sun, X., Bai, A., Zhang, C., Li, L., Enjyoji, K., Junger, W. G., Robson, S. C., & Wu, Y.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-02
- Volume
- 8
- Issue
- 4
- Pages
- e60184
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2016467209
- Cited by
- 123
- References
- 14
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.